Our professionals represented Ariosa Diagnostics (which was acquired by Roche Molecular Systems) in a bet-the-company case regarding technology involving the use of massively parallel sequencing for the detection of nucleic acid of fetal origin in maternal serum or plasma. Gardella Grace prevailed in multiple inter partes review proceedings.

Petitions can be found here and here.
The related reexamination request can be found here.